Overview

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma

Status:
Completed
Trial end date:
2016-01-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine a dose for future development and to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy profiles of JNJ-42756493 in Japanese and other Asian patients with advanced or refractory solid tumors or lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC